Physician profile
Aristotle Mendiola
NPI 1871518266
$6,960.22
in general payments reported to CMS, 2019-2025
25 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,374 · 2020: $340 · 2021: $417 · 2022: $497 · 2023: $1,477 · 2024: $1,574 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,168 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,168.11 |
| Education | $163.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,135.24 | 2019-2025 | |
| Gilead Sciences, INC. | $805.82 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $786.98 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $708.87 | 2019-2025 | Stelara, Tremfya, Simponi |
| Pfizer INC. | $505.18 | 2019-2025 | |
| Lilly USA, LLC | $392.07 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $285.48 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.78 | 2019-2024 | Xifaxan |
| Qol Medical, LLC | $221.31 | 2019-2024 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $125.73 | 2019-2024 | |
| Genzyme Corporation | $95.94 | 2023 | |
| Medtronic, INC. | $92.74 | 2024-2025 | Gi Genius |
| Ferring Pharmaceuticals INC. | $85.92 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $73.55 | 2024-2025 | Voquezna |
| Ucb, INC. | $63.55 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $62.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Shire North American Group INC | $44.15 | 2019 | |
| Novo Nordisk INC | $36.08 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $34.66 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $23.99 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.79 | 2023 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $23.03 | 2025 | Iqirvo |
| Redhill Biopharma INC. | $20.98 | 2021 | |
| Celgene Corporation | $18.40 | 2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aristotle Mendiola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.